Creative Wear Out in a Multi-Screen Ecosystem 

Why audience frequency is pharma’s next competitive advantage 

For years, pharma marketers chased reach. Today the harder job is holding attention. Patients, caregivers and healthcare professionals (HCPs) now consume media across nearly endless content in a complex environment, moving fluidly and endlessly across Linear TV, Connected TV (CTV), streaming, online video (OLV), social video, retail media and professional content environments throughout the day. At the same time, video ad investment continues to fragment and shift toward digital video channels. U.S. digital video ad spend is projected to hit $81.9 billion in 2026 and, for the first time, claim 61% of all TV and video dollars, with pharmaceutical the fourth-largest category at $7.4 billion. More screens, more money and often the same handful of approved spots. That’s how creative wear out sneaks up on a brand: not in one channel, but across all of them. 

One ordinary day, two viewers, one brand 

Picture a single Rx brand running DTC and HCP video at the same time. Now, follow me and a physician I’ll call Dr. McDreamy, through an ordinary day. 

Every platform report says frequency looks fine. The person on the couch would disagree. 

Wear out is now an audience problem, not a channel problem 

Viewers don’t necessarily split “TV,” “streaming,” and “social” video touchpoints the way media planners do. Deloitte found 41% of consumers count both streaming and social video as watching TV. This does not make a social video impression equal to a full-screen CTV ad; but both add to the same person’s total exposure. Yet most frequency caps still live inside a single publisher, platform or DSP, so cross-channel repetition goes largely unmonitored. The trade-off is reduced attention. A 2026 Journal of Advertising Research study found attention to repeated ads drops faster on CTV than on linear TV, and the gap widens when the same spot runs several times in a day or hour. Big screens and long, lean-in sessions, like binge-watching a newly dropped season, make a repeated spot hard to miss: 62% of U.S. streaming subscribers say they’ve seen the same ad multiple times in one sitting. The upside is worth protecting. In CMI Media Group’s 2026 Media Vitals™ Consumer research, TV healthcare ads were among the most remembered (only 11% couldn’t recall one) and 41% of consumers found them helpful. Overexposure is how a helpful ad becomes an annoying one. 

Why pharma feels it first 

• Fewer approved video assets, longer approvals. MLR review, fair balance and ISI requirements already slow creative refresh. The FDA’s DTC enforcement push that began in September 2025 raised the bar for TV creative and a proposed rule to eliminate the “adequate provision” standard is expected in December 2026. 

• Small HCP universes stack frequency fast. Tight target lists mean the same physicians absorb most of the impressions and they notice. In a 2026 survey, 58% of HCPs said most digital pharma content feels repetitive or irrelevant and 65% had reduced or stopped engaging with a company after a poor digital experience. 

• HCPs are consumers, too. 89% of physicians watch TV between 6 and 11 PM, 64% stream and fewer are paying for ad-free tiers. And TV is where they notice us. According to our Media Vitals research, 34% of HCPs say they frequently or always notice pharma ads while watching TV, more than when reading print medical journals (31%) or visiting medical news sites (21%). Your DTC plan is reaching your HCP targets whether you count it or not. 

Smarter exposure management: five moves 

The answer isn’t less frequency. It’s smarter frequency, planned audience first, inventory second, outcomes third. 

1. Plan to the person, not the platform. Measure deduplicated reach and audience-level frequency across Linear TV, CTV, OLV and social video using privacy-safe, HIPAA-compliant identity and clean-room partners. Set one cross-screen frequency ceiling instead of five channel caps and include HCPs who see your DTC work at night. 

2. Pick inventory that can share the load. Favor partners and buying paths that support cross-publisher frequency capping and consolidate supply where streaming overlap drives duplicate impressions. 

3. Build refresh into the media plan and the MLR calendar. Approve a modular creative system up front, with :06/:15/:30/:60 cutdowns, alternate openings and compliant ISI treatments, so creative rotation is scheduled rather than reactive. 

4. Sequence the story. Move audiences from awareness to education to action instead of replaying the same :30. That’s what CMI Media Group’s Empower ™ AMO (Automated Media Orchestration) was built to do. It reads how each audience engages and serves the next best action/message in the sequence, not the same one again. If a consumer or HCP tunes out one message stream, AMO moves them to a fresh one automatically. That’s sequencing at scale, with more than 200 campaigns and $1 billion in incremental revenue for CMI Media Group clients. Then sync with the field activity, too: Veeva found coordinated sales and marketing lifts marketing effectiveness 23%, yet 65% of HCP engagements remain unsynchronized. 

5. Measure wear out, not just delivery. Served isn’t seen. Only 13% of HCPs frequently notice pharma ads in online video, compared with 34% on TV. Track attention and brand lift by frequency band, then set wear out triggers that cue a creative rotation before performance slips. 

Now put the five moves together. Same day, same screens, a very different experience 

Dr. McDreamy’s day isn’t a wish list. It’s the kind of HCP sequence our Empower AMO platform is built to run, across thousands of physicians at once. 

Conclusion 

Pharma has spent years optimizing where ads run in silos. The next edge comes from optimizing how people experience them across channels. At 9 PM, Dr. McDreamy and I are watching the same show and seeing the same spot. Brands that proactively plan for that moment will protect attention, respect the viewer and get more out of every video dollar. In a multi-screen world, protecting attention matters as much as buying reach.